2B78:XETRA:XETRA-iShares Healthcare Innovation UCITS ETF USD (Acc) (EUR)

ETF | Others |

Last Closing

USD 6.913

Change

0.00 (0.00)%

Market Cap

USD 1.14B

Volume

0.10M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.66 (+1.30%)

USD 548.90B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.21 (+1.26%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.31 (+1.16%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.33 (+1.20%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.34 (+1.42%)

USD 157.79B
8R80:XETRA Amundi Index Solutions - Amund..

+1.70 (+1.16%)

USD 103.20B
JARI:XETRA Amundi Index Solutions - Amund..

+0.45 (+1.01%)

USD 102.92B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.67 (+1.32%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+1.34 (+0.25%)

USD 80.38B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

+0.28 (+1.28%)

USD 79.79B

ETFs Containing 2B78:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.38% 32% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.38% 32% F 36% F
Trailing 12 Months  
Capital Gain 0.90% 18% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.90% 18% F 25% F
Trailing 5 Years  
Capital Gain 22.09% 48% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.09% 46% F 48% F
Average Annual (5 Year Horizon)  
Capital Gain 5.66% 56% F 55% F
Dividend Return 5.66% 55% F 53% F
Total Return N/A 2% F 2% F
Risk Return Profile  
Volatility (Standard Deviation) 22.26% 15% F 28% F
Risk Adjusted Return 25.44% 43% F 44% F
Market Capitalization 1.14B 81% B- 72% C

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.